Prof. R. (Ronald) de Wit, PhD

I am Medical Oncologist, senior staff member and full professor at the Erasmus MC Cancer Institute.

My research focus is Genito-Urinary Oncology. I have chaired the EORTC-Genitourinary Group Chemotherapy Subcommittee for many years and initiated and led randomized studies in testicular cancer, renal, prostate and bladder cancer. I am still involved in a wide variety of ongoing clinical and translational studies. I supervise 6-8 PhD students in the field of clinical and preclinical reserarch in GU cancers.

My research focus is Genito-Urinary Oncology.

I co-chaired several registration trials, ranging from chemotherapy and AR targeted agents in mCRPC, to recent checkpoint inhibition (PD-1) trials in bladder cancer. I am currently involved in a wide variety of ongoing clinical studies and serve on Industry Advisory Board Committees, as well as Data Monitoring Committees.

In 2011 I launched the Dutch Uro Oncology Study Group (www.stichtingduos.nl) creating a collaborative network of 25 hospitals in the Netherlands and am Chairman of the Group.

I earned my medical degree at the University of Amsterdam and specialized in Internal Medicine and Medical Oncology (1982-1990).After obtaining my PhD (HIV-associated cancer 1990).

I continued my career at the ErasmusMC Cancer Institute, formerly Daniel den Hoed Cancer Center. In 2009 I obtained a full professorship in Experimental systemic treatment of Genito-Urinary cancers.

Post-graduate lecturer on the management of GU cancers for ESMO, aside from the annual main European meeting, I give annual lectures at ESMO-Americas, ESMO-Africa, ESMO-Middle East and ESMO-Asia.

Founding ( 2011) Chairman of the Dutch Uro-Oncology Study group, a network comprising 26 university and supraregional hospitals in the Netherlands. Member of a wide range of professional societies and committees; serving as Faculty and Program Committee Member/ Committee Chair for the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO).

Research groups:

The clinical research program in Genito-urinary Oncology comprises the entire spectrum of phase 1-3 clinical trials, both Industry as well as investigator initiated studies and is embedded in the Department’s research programs Translational Cancer Genomics and Proteomics, Translational Pharmacology and Translational Onco-Immunology. Clinical and preclinical research activities are highly complementary: findings coming forth from preclinical studies are assessed for their clinical value and clinical questions lead to novel preclinical studies. There is well-established collaboration with the Departments of Urology, Uro-Pathology, Molecular Diagnostic Pathology, and Radiotherapy. There is an extensive collaboration with partners from academia and industry, both nationally and internationally.

Research projects:

The clinical research program in Genito-urinary Oncology, including the entire spectrum of phase 1-3 clinical trials, both Industry as well as investigator initiated studies, is embedded in the Department’s research programs Translational Cancer Genomics and Proteomics, Translational Pharmacology and Translational Onco-Immunology. There is well-established collaboration with the Departments of Urology, Uro-Pathology, Molecular Diagnostic Pathology, Computational Sciences, Radiotherapy and Nuclear Medicine. I have an extensive collaboration with partners from academia and industry, both nationally and internationally.

Mannen met prostaatkanker: maak een second opinion bespreekbaar. Die oproep doet internist-oncoloog prof. Ronald de Wit van het Erasmus MC Kanker Instituut in de podcast In Opname. Volgens hem vragen niet genoeg prostaatkankerpatiënten om een second opinion

  

De podcast is onder andere te beluisteren via:

• Apple Podcast
• Spreaker
• Spotify
• Google Podcast